Ad is loading...
DFFVX vs QRSIX
DFFVX vs QRSIX Comparison
Open Charts DFFVX vs QRSIX
DFA US Targeted Value I
Price$30.36
Change+$0.58 (+1.95%)
VolumeN/A
Net Assets11.69B
FPA Queens Road Small Cap Value Instl
Price$37.10
Change+$0.79 (+2.18%)
VolumeN/A
Net Assets789.45M
DFFVX vs QRSIX Comparison Chart
Loading...
View a ticker or compare two or three
VS
VS
FUNDAMENTALS
Fundamentals
DFFVX has more cash in the bank: 11.7B vs. QRSIX (789M). DFFVX pays higher dividends than QRSIX: DFFVX (1.63) vs QRSIX (0.95). DFFVX was incepted earlier than QRSIX: DFFVX (25 years) vs QRSIX (4 years). QRSIX (0.79) is less costly to investors than DFFVX (0.30). QRSIX is a more actively managed with annual turnover of: 13.00 vs. DFFVX (7.00). DFFVX has a lower initial minimum investment than QRSIX: DFFVX (0) vs QRSIX (100000). QRSIX annual gain was more profitable for investors over the last year : -0.36 vs. DFFVX (-6.12).
| DFFVX | QRSIX | DFFVX / QRSIX | |
| Total Expense Ratio | 0.29 | 0.79 | 37% |
| Annual Report Gross Expense Ratio | 0.30 | 0.79 | 38% |
| Fund Existence | 25 years | 4 years | - |
| Gain YTD | -14.027 | -6.802 | 206% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 100000 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 11.7B | 789M | 1,483% |
| Annual Yield % from dividends | 1.63 | 0.95 | 171% |
| Returns for 1 year | -6.12 | -0.36 | 1,699% |
| Returns for 3 years | 4.65 | 9.17 | 51% |
| Returns for 5 years | 108.04 | N/A | - |
| Returns for 10 years | 34.47 | N/A | - |
View a ticker or compare two or three
VS
VS
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| RICBX | 54.36 | 1.21 | +2.28% |
| American Funds Invmt Co of Amer R2 | |||
| FSAEX | 11.16 | N/A | N/A |
| Fidelity Series All-Sector Equity | |||
| ADRRX | 17.08 | N/A | N/A |
| American Century Disciplined Growth R | |||
| PZINX | 10.98 | N/A | N/A |
| Pzena International Value Instl | |||
| ETAHX | 29.33 | N/A | N/A |
| Eventide Healthcare & Life Sciences A | |||